文献速递细菌感染、耐药与抗菌药物医院感染防控

新加坡成人住院患者碳青霉烯耐药肠杆菌的临床与分子流行病学

Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该研究分析了2010至2015年新加坡成人住院患者碳青霉烯耐药肠杆菌(CRE)的临床与分子流行病学。临床培养CRE发病率在2010至2012年末初始上升后,于2013年趋于平稳(范围7.73-10.32/10万患者日)。前瞻性纳入249例受试者,其中64.7%产碳青霉烯酶;既往碳青霉烯暴露(OR: 3.23; 95%CI: 1.67-6.25)和血液恶性肿瘤(OR: 2.85; 95%CI: 1.10-7.41)与非产碳青霉烯酶CRE相关。

要点

  • 2013年后成人住院患者CRE临床培养发病率趋于平稳。
  • 既往碳青霉烯暴露与血液恶性肿瘤与非产碳青霉烯酶CRE相关。
  • 全基因组测序检测到5个传播簇,涉及13名受试者。

核心结论

  • 成人住院患者CRE临床趋势在2010年快速上升后趋于稳定,可能归因于感染防控措施和抗菌药物管理。
  • 需进一步研究产碳青霉烯酶肠杆菌的传播动力学。

研究设计与样本

  • 基于国家公共卫生实验室强制数据的回顾性分析,估算2010至2015年CRE临床和监测培养的季度发病率。
  • 2013年12月至2015年4月从6家公立医院前瞻性招募CRE阳性成人住院患者,进行标准化流行病学问卷和电子病历信息提取。
  • 对研究分离株进行全基因组测序以确定传播簇。
  • 前瞻性纳入249名受试者,中位年龄65岁,108名(43%)为女性,161名(64.7%)产碳青霉烯酶。

主要发现

  • 成人住院患者CRE临床培养发病率从2013年起趋于平稳,范围为7.73至10.32/10万患者日。
  • 多变量分析显示,既往碳青霉烯暴露(OR: 3.23; 95%CI: 1.67-6.25)和血液恶性肿瘤(OR: 2.85; 95%CI: 1.10-7.41)与非产碳青霉烯酶CRE(n=88)相较于产碳青霉烯酶CRE(n=161)相关。
  • 249名受试者的430株CRE分离株中,307株(71.3%)产碳青霉烯酶,其中154株(50.2%)blaKPC阳性,97株(31.6%)blaNDM阳性,42株(13.7%)blaOXA阳性。
  • 主要肠杆菌科菌种为肺炎克雷伯菌(n=180, 41.9%)、大肠埃希菌(n=129, 30.0%)和阴沟肠杆菌(n=62, 14.4%)。
  • 全基因组测序(n=206)显示菌株ST型多样;主要blaKPC阳性质粒为pHS102707(n=62, 55.4%),主要blaNDM阳性质粒为pNDM-ECS01(n=46, 48.9%);检测到5个传播簇涉及13名受试者。

临床怎么用

  • 应关注既往碳青霉烯暴露和血液恶性肿瘤患者中非产碳青霉烯酶CRE的风险。
  • 感染防控措施和抗菌药物管理可能有助于稳定CRE发病率。
  • 全基因组测序可用于识别CRE传播簇,指导感染控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2010, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) has been increasing in Singapore. We analyzed the clinical and molecular epidemiology of CRE among adult inpatients in Singapore. METHODS: Quarterly incidence of unique subjects (per 100000 patient-days) with positive clinical and surveillance cultures for CRE were estimated based on mandatory data submitted to the National Public Health Laboratory by public hospitals between 2010 and 2015. CRE-positive adult inpatients were prospectively recruited from 6 public sector hospitals between December 2013 and April 2015. Subjects answered a standardized epidemiologic questionnaire and provided samples for this study. Further clinical information was extracted from subjects' electronic medical records. Whole-genome sequencing was performed on study isolates to determine transmission clusters. RESULTS: Incidence of CRE clinical cultures among adult inpatients plateaued from 2013 (range: 7.73 to 10.32 per 100000 patient-days) following an initial increase between 2010 and end-2012. We prospectively recruited 249 subjects. Their median age was 65 years, 108 (43%) were female, and 161 (64.7%) had carbapenemase-producing Enterobacteriaceae (CPE). On multivariate analysis, prior carbapenem exposure (OR: 3.23; 95% CI: 1.67-6.25) and hematological malignancies (OR: 2.85; 95% CI: 1.10-7.41) were associated with non-carbapenemase-producing CRE (NCPE) (n = 88) compared with CPE (n = 161) subjects. Among 430 CRE isolates from the 249 subjects, 307(71.3%) were CPE, of which 154(50.2%) were blaKPC-positive, 97(31.6%) blaNDM-positive, and 42 (13.7%) blaOXA-positive. Klebsiella pneumoniae (n = 180, 41.9%), Escherichia coli (n = 129, 30.0%) and Enterobacter cloacae (n = 62, 14.4%) were the main Enterobacteriaceae species. WGS (n = 206) revealed diverse bacterial strain type (STs). The predominant blaKPC-positive plasmid was pHS102707 (n = 62, 55.4%) and the predominant blaNDM-positive plasmid was pNDM-ECS01 (n = 46, 48.9%). Five transmission clusters involving 13 subjects were detected. CONCLUSIONS: Clinical CRE trend among adult inpatients showed stabilization following a rapid rise since introduction in 2010 potentially due to infection prevention measures and antimicrobial stewardship. More work is needed on understanding CPE transmission dynamics.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Marimuthu K, Venkatachalam I, Khong WX, et al. Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore. Clin Infect Dis. 2017. PMID: 28475792. doi:10.1093/cid/cix113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。